From bench to bedside – Developing an osteosarcoma precision oncology workflow

Dr Jacqui McGovern from Queensland University of Technology is researching drug responses to determine effective and individual therapeutic treatment options.
Dr Jacqui McGovern from Queensland University of Technology is researching drug responses to determine effective and individual therapeutic treatment options.

Recipient: Dr Jacqui McGovern
Institute: Queensland University of Technology
Funding: $299,171 June 2022 to July 2025 (The Kids' Cancer Project: $199,171 and The Tie Dye Project: $100,000)

Osteosarcoma is the most common malignant bone tumour affecting children and adolescents. 

Importantly, clinical outcomes have not improved for decades, and bone tumours remain a leading cause of cancer-related death in adolescents.

Precision oncology has the potential to advance treatment options, yet its widespread application is hindered by complex methodologies. 

Using state-of-the-art technologies to mimic the tumour microenvironment, this study aims to analyse drug responses to determine effective therapeutic options specific to the individual tumour. This will accelerate the translation of precision medicine from bench-to-bedside for childhood sarcoma patients.